Sanofi India Ltd

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest day decline of 0.17%, the stock’s technical parameters reveal a complex picture that investors should carefully analyse amid broader market pressures and sector dynamics.

Sanofi India Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing challenges in financial performance and long-term growth. The upgrade, effective from 5 May 2026, is driven primarily by a shift in technical indicators, attractive valuation relative to peers, and strong management efficiency, though tempered by subdued sales growth and recent profit declines.

Sanofi India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest day change of 0.07%, the stock’s technical parameters reveal a nuanced picture that investors and analysts must carefully consider amid broader market trends.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

A sustained decline has pushed Sanofi India Ltd to a fresh 52-week low of Rs 3,151.05 on 30 Mar 2026, marking a significant 53% drop from its peak of Rs 6,717.50 within the last year. This downturn comes despite pockets of strength in the company’s fundamentals, highlighting a complex interplay of market and company-specific factors.

A sharp decline in Sanofi India Ltd has dragged the stock to a fresh 52-week low of Rs 3190.3 on 27 Mar 2026, marking a 45.64% drop over the past year and signalling sustained pressure amid broader market weakness.

For the fifth straight session, Sanofi India Ltd closed lower, breaching its 52-week low at Rs 3,202.7 on 24 Mar 2026, marking a cumulative decline of 7.2% over this period.

For the third consecutive session, Sanofi India Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 3,270 on 23 Mar 2026. This marks a significant 51.3% drop from its 52-week high of Rs 6,717.5, underscoring a sustained period of weakness amid broader market volatility.

A sustained decline has pushed Sanofi India Ltd to a fresh 52-week low of Rs 3402.05 on 20 Mar 2026, marking a significant 49.4% drop from its peak of Rs 6717.5 over the past year. This downturn contrasts sharply with the broader market, where the Sensex has gained 1.09% today and remains only 4.79% above its own 52-week low.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sanofi India Ltd’s share price has declined to a new 52-week low, closing just 0.06% above the lowest price of Rs 3,415.8. This marks a significant downturn for the pharmaceutical company, reflecting ongoing challenges in its financial performance and market positioning over the past year.

Sanofi India Ltd’s stock price declined to a fresh 52-week low of Rs.3420 on 16 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have been under pressure, reflecting a combination of subdued financial performance and broader market weakness.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3585.65 on 13 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has now recorded losses for 11 consecutive trading sessions, shedding 13.36% during this period, reflecting persistent pressures within the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3587.85 on 12 Mar 2026, marking a significant milestone in a sustained downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a combination of subdued financial results and extended negative momentum.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3650.1 today, marking a continuation of a downward trajectory that has seen the stock lose over 11.6% in the past nine trading sessions. This latest low reflects ongoing pressures on the pharmaceutical company’s market performance amid broader sector and market headwinds.